SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciae291 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Joshua A Hill und 29 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease, Fred Hutchinson Cancer Center, and Department of Medicine, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, COVID-19 Vaccines, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Janssen/Johnson & Johnson, OptumHealth, Takeda Oncology Co.
Abstract (Originalsprache)
Background
The optimal timing of vaccination with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines after cellular therapy is incompletely understood. The objectives of this study are to determine whether humoral and cellular responses after SARS-CoV-2 vaccination differ if initiated <4 months versus 4–12 months after cellular therapy.
Methods
We conducted a multicenter, prospective, observational study at 30 cancer centers in the United States. SARS-CoV-2 vaccination was administered as part of routine care. We obtained blood prior to and after vaccinations at up to 5 time points and tested for SARS-CoV-2 spike (anti-S) IgG in all participants and neutralizing antibodies for Wuhan D614G, Delta B.1.617.2, and Omicron B.1.1.529 strains, as well as SARS-CoV-2–specific T-cell receptors, in a subgroup.
Results
We enrolled 466 allogeneic hematopoietic cell transplantation (HCT) (n = 231), autologous HCT (n = 170), and chimeric antigen receptor T-cell (CAR-T-cell) therapy (n = 65) recipients between April 2021 and June 2022. Humoral and cellular responses did not significantly differ among participants initiating vaccinations <4 months versus 4–12 months after cellular therapy. Anti-S IgG ≥2500 U/mL was correlated with high neutralizing antibody titers and attained by the last time point in 70%, 69%, and 34% of allogeneic HCT, autologous HCT, and CAR-T-cell recipients, respectively. SARS-CoV-2–specific T-cell responses were attained in 57%, 83%, and 58%, respectively. Pre–cellular therapy SARS-CoV-2 infection or vaccination and baseline B-cell count were key predictors of post–cellular therapy immunity.
Conclusions
These data support mRNA SARS-CoV-2 vaccination prior to, and reinitiation 3 to 4 months after, cellular therapies with allogeneic HCT, autologous HCT, and CAR-T-cell therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vaccine and Infectious Disease, Fred Hutchinson Cancer Center, and Department of Medicine, University of Washington, Seattle, Washington, USA.
- Center for International Blood and Marrow Transplantation Research, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Division of Infectious Diseases, University of Minnesota, Minneapolis, Minnesota, USA.
- Adaptive Biotechnologies Corporation, Seattle, Washington, USA.
- Division of Infectious Diseases, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
ORCID-Profile: Joshua A Hill
Förderung
- Janssen/Johnson & Johnson
- OptumHealth
- Takeda Oncology Co
- Miltenyi Biotec, Inc
- Janssen Research & Development, LLC
- Xenikos BV
- Talaris Therapeutics
- Kyowa Kirin
Zitieren
APA
Hill, J. A., Martens, M. J., Young, J. H., Bhavsar, K., Kou, J., Chen, M., Lee, L. W., Baluch, A., Dhodapkar, M. V., Nakamura, R., Peyton, K., Howard, D. S., Ibrahim, U., Shahid, Z., Armistead, P., Westervelt, P., McCarty, J., McGuirk, J., Hamadani, M., …, & Perales, M. A. (2024). SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae291
Vancouver
Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, et al. SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae291
BibTeX
@article{Hill2024,
author = {Hill, Joshua A and Martens, Michael J and Young, Jo-Anne H and Bhavsar, Kavita and Kou, Jianqun and Chen, Min and Lee, Lik Wee and Baluch, Aliyah and Dhodapkar, Madhav V and Nakamura, Ryotaro and Peyton, Kristin and Howard, Dianna S and Ibrahim, Uroosa and Shahid, Zainab and Armistead, Paul and Westervelt, Peter and McCarty, John and McGuirk, Joseph and Hamadani, Mehdi and DeWolf, Susan and Hosszu, Kinga and Sharon, Elad and Spahn, Ashley and Toor, Amir A and Waldvogel, Stephanie and Greenberger, Lee M and Auletta, Jeffery J and Horowitz, Mary M and Riches, Marcie L and Perales, Miguel-Angel},
title = {SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae291}
}
EUVIMED